Discover how inebilizumab reduces flares and improves remission rates in IgG4-related disease in this phase 3 clinical trial.

Novartis has claimed the top spot in the 2024 Access to Medicine Index, displacing GSK after 16 consecutive years at the top.

A NEW study has leveraged machine learning to identify factors and develop predictive models for successfully discontinuing ...

RECENT data shows a significant increase in germline genetic testing (GGT) for prostate cancer, with a notable rise in ...

VR/AR headsets could one day match desktops in diagnostic effectiveness, according to a recent study. Read more.

Glucagon-like peptide-1 receptor (GLP-1) agonists, particularly semaglutide, could be effective in reducing alcohol-related ...

Discover a trial in which patients received either IL-2 or a placebo for 5 days, followed by weekly doses for 4 weeks.

Patients with relapsed/refractory multiple myeloma could benefit from repeat treatment with drugs their disease has ...

CAR T-cell therapy shows promise for solid tumors like glioblastoma. New engineering strategies and clinical trial results ...

NOVEL molecular regulators of rheumatoid arthritis (RA) inflammation were presented as part of a plenary abstract session at ...

A recent systematic review and meta-analysis reveals dermatologists have a significantly higher accuracy in diagnosing skin ...

No significant difference found between hydrocortisone replacement and prednisone tapering for glucocorticoid discontinuation ...